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Abstract
Background: There are limited data concerning patients treated with sequential bilateral kidney surgery. Current
guidelines still lack an optimal surgical sequencing approach. We evaluated renal functional outcomes after
sequential partial nephrectomy (PN) and radical nephrectomy (RN) in patients with bilateral renal cell carcinoma
(RCC).
Methods: A propensity score matched cohort of 267 patients (synchronous bilateral RCCs, N = 44 [88 lesions];
metachronous bilateral, N = 45 [90 lesions]; unilateral, N = 178) from two tertiary institutions were retrospectively
analyzed. Synchronous bilateral RCCs were defined as diagnosis concomitantly or within 3 months of former tumor.
Renal functional outcomes were defined as estimated glomerular filtration rate (eGFR) changes and de novo
chronic kidney disease (CKD, stage ≥3) after surgery. Renal functional outcomes and clinical factors predicting de
novo CKD were assessed using descriptive statistics and Cox regression analysis.
Results: In subgroup of bilateral RCCs, patients underwent sequential PN (N = 48), PN followed by RN (N = 8), or RN
followed by PN (N = 25). Final postoperative estimated glomerular filtration rates (eGFRs) were 79.4, 41.4, and 61.2
ml/minute/1.73 m2, respectively (p = 0.003). There were significant differences in eGFR decline from baseline and de
novo chronic kidney disease (CKD stage ≥ III) among groups, with PN followed by RN group showing the worst
functional outcomes (all p < 0.05). Moreover, sequential PN subgroup in bilateral RCC showed significantly higher
rate of de novo CKD than unilateral RCC group (13.8% vs. 6.9%, p = 0.016). On multivariate analysis, hypertension
(p = 0.010) and surgery sequence (PN followed by RN, p < 0.001) were significant predictors of de novo CKD.
Conclusions: The surgery sequence should be prudently determined in bilateral renal tumors. PN followed by RN
showed a negative impact on renal functional preservation. Nephron-sparing surgery should be considered for all
amenable bilateral RCCs.
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Introduction
It has been estimated that 73,800 new cases of cancers
of the kidney and renal pelvis will be diagnosed in the
United States in 2020 and that 14,800 people will die of
them [1]. Approximately 85% of all kidney tumors are
renal cell carcinoma (RCC). RCC occurs in bilateral kid-
neys, including synchronous RCC (diagnosed concomi-
tantly or within 3 months of the former tumor) and
metachronous RCC (tumor diagnosed 3 months after
former tumor detection) in approximately 5% of all RCC
patients [2–5]. Due to the relative rarity of bilateral pres-
entation, even until now, there are limited data in the lit-
erature concerning patients treated with sequential
bilateral kidney surgery. Few literatures have evaluated
the functional impact of bilateral kidney surgery and
how functional outcomes are influenced by tumor char-
acteristics, modality selection, and patient-related risk
factors [6–9].
Nevertheless, several studies have elucidated renal func-
tional outcomes in patients with bilateral synchronous tu-
mors who have undergone sequential bilateral kidney
surgery. Simmons et al. have demonstrated that bilateral
partial nephrectomy (PN) is associated with significantly
improved estimated glomerular filtration rate (eGFR)
compared to radical nephrectomy (RN) [6]. Packiam et al.
have reported that patients for nonmetastatic bilateral
synchronous tumors who have received simultaneous PN
show lower mean postoperative 3months (− 6% vs. -24%,
p = 0.015) and median postoperative 12months (− 4% vs.
-22%, p < 0.001) reduction in eGFR compared to staged
(within 6months) PN, respectively [7]. Singer et al. have
observed that nephron-sparing surgery (NSS) enables dia-
lysis to be avoided in more than 95% of patients [8]. An-
other study reported average 28.9% eGFR decline after
treatment of both kidneys with 608-day follow-up (59→
41.9ml/min/1.73m2) [9].
However, few studies have compared long term func-
tional outcomes according to procedure sequence.
Current guidelines still lack an optimal surgical sequen-
cing approach [10–12]. Therefore, the objective of this
study was to evaluate renal functional outcomes after se-
quential PN and RN in patients with bilateral RCC.
Materials and methods
Ethics statement
The Institutional Review Board of the Seoul National
University Bundang Hospital approved this study (Ap-
proval number: B-2007-625-102). As the present study
was carried out retrospectively, written informed con-
sent from patients was waived. Personal identifiers were
completely removed and data were analyzed anonym-
ously. Our study was conducted according to ethical
standards recommended by the 1964 Declaration of
Helsinki and its later amendments.
Study cohort
From June 2003 to March 2018, a total of 267 patients
(synchronous bilateral RCCs, N = 44 [88 tumor lesions];
metachronous bilateral RCCs, N = 45 [90 lesions]; unilat-
eral RCCs, N = 178) from two tertiary institutions
(SNUH and SNUBH) were included in this study. Syn-
chronous bilateral RCCs were defined as diagnoses con-
comitantly or within 3 months of the former tumor.
Metachronous bilateral RCCs were defined as tumor
diagnoses at intervals of at least 3 months. All included
patients underwent surgery by open, laparoscopic, or ro-
botic approach which was left to surgeon discretion,
with curative intent in two centers [4–7]. Main operat-
ing surgeons determine the sequence of surgery under
consideration of patients’ clinical setting and multidis-
ciplinary consultation. In general, treatment for the lar-
ger tumor was implemented first to allow better tumor
control and the contralateral kidney to assist in recovery
of renal function (Fig. 1). Variation in time between sur-
geries can be attributed to differences in recovery speed
from initial surgery, patients’ willingness to receive sub-
sequent surgery, and preoperative general medical con-
ditions. Patients were excluded if they had non-RCC
histology or hereditary kidney diseases (e.g., the von
Hippel-Lindau [VHL] disease, autosomal dominant poly-
cystic kidney disease [ADPKD], Birt-Hogg-Dubé [BHD]
syndrome, and so on). Clinical data in medical records
were retrospectively reviewed [13].
Acquisition and definition of data
Clinical perioperative variables included age, gender,
body mass index (BMI), past medical history (including
diabetes mellitus [DM], hypertension [HTN], and
chronic kidney disease [CKD]), symptoms at presenta-
tion, Eastern Cooperative Oncology Group (ECOG) per-
formance status, and types of surgery (PN vs. RN).
Pathological parameters including histological type ac-
cording to the World Health Organization (WHO) clas-
sification system, pathologic stage according to the 8th
edition of American Joint Committee guidelines, Fuhr-
man nuclear grade, and positive surgical margin were
also evaluated [14, 15]. Tumor sizes are defined as the
longest length of axes measured from pathologic speci-
men after surgery. Ischemic time is defined as warm is-
chemia time from first arterial clamping to first arterial
unclamping. These are all monitored at the time of op-
eration by main operating surgeon. Renal functional out-
comes were defined as estimated glomerular filtration
rate (eGFR) changes and incidence of de novo CKD
(stage ≥3) after surgery. eGFR changes at specific post-
operative period was evaluated as follows: differences be-
tween postoperative 1 week eGFR and preoperative
baseline eGFR, between postoperative 1 month eGFR
and baseline eGFR, between postoperative 1 year eGFR
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and baseline eGFR, and between latest eGFR and base-
line eGFR. Renal functional evaluation was conducted
using serum creatinine values obtained immediately be-
fore initial surgery, immediately before second surgery,
and 3 to 6 months after the second surgery. Modification
of Diet in Renal Disease equation was used to calculate
eGFR [16]. CKD staging was conducted according to the
National Kidney Foundation Disease Outcomes Quality
Initiative Clinical Practice Guidelines [17].
Follow-up protocol
According to institutional standardized postoperative
protocol, patients were generally followed-up after sur-
gery at least every 6 months in the first year, annually
during the next 4 years, and every 2 years thereafter.
Follow-up protocols consisted of blood test including
serum creatinine, computed tomography or magnetic
resonance imaging studies, and chest radiography.
Statistical analyses
Clinicopathological characteristics were compared be-
tween unilateral and bilateral RCC groups using Chi-
squared test or Kruskal-Wallis test for categorical vari-
ables and one-way analysis of variance, independent t-
test or Mann-Whitney U test for continuous variables as
appropriate. Univariate and multivariate Cox-
proportional hazard regression analyses were performed
to evaluate significant variables associated with de novo
CKD within postoperative 1 year and along entire
follow-up period. Proportional hazard assumptions were
evaluated using Schoenfeld test and log-log plot. The
univariate results were used to determine the candidate
variables for the final multivariate model in a backward
model selection process. In all variables remaining in the
final multivariate analysis, the p value was set to 0.05.
Age, hypertension, pathologic tumor size, surgery se-
quence, and tumor chronology (only for Table 6) are
variables included in the multivariate analysis at both
Tables 5 and 6. In addition, eGFR changes and clinical
factors predicting de novo CKD in the propensity score
matched cohort were assessed using descriptive statistics
and Cox regression analysis [18]. The propensity score
matching (PSM) was used to control other confounding
factors when analyzing renal functional outcomes of uni-
lateral and bilateral RCCs. The propensity scores
matched using the nearest neighbor, 1:1 pair matching
within 0.2 standard deviations (SDs) of the logit of the
propensity score. By calculating the standardized differ-
ences of the means or proportions of each covariate after
matching, baseline covariates with standardized differ-
ences < 0.1 indicated a good balance between groups.
Age, sex, DM, HTN, CKD, BMI, ECOG performance
Fig. 1 Treatment algorithm
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status, baseline eGFR, surgical type, expected blood loss,
ischemic time, and pathologic tumor size was used as
covariates in the PSM process. Subgroup analysis of bi-
lateral RCC among synchronous and metachronous
RCCs was also performed. All statistical analyses were
performed using commercially available software IBM
SPSS Statistics ver. 21.0 (Armonk, NY, USA and the
statistical package for R, ver. 2.13.2 (R Foundation for
Statistical Computing [http://www.r-project.org/]). Two-
sided p values < 0.05 were considered statistically
significant.
Results
Baseline characteristics between bilateral RCC group
and unilateral RCC group are detailed in Table 1. Pre-
propensity table for the cohort before matching are de-
tailed in supplementary Table 1. There were no signifi-
cant differences in baseline characteristics between
groups after propensity score matching. Median time be-
tween surgeries in bilateral RCC group was 146.0 days
(37.5 days for synchronous and 1899.0 days for meta-
chronous subgroup). In the bilateral RCC cohort, sub-
group comparative analysis for renal functional outcome
(PN followed by PN vs. PN followed by RN vs. RN
followed by PN group) was conducted (Table 2). Patients
underwent sequential PN (n = 48), PN followed by RN
(n = 8), or RN followed by PN (n = 25). Patients with
sequential RN were excluded in the subgroup analysis
due to intuitively prominent renal function deterioration
compared to other groups. The mean eGFR follow-up
duration was 65.6 ± 47.6 months (range, 0–166 months).
Final eGFR after bilateral surgery was 79.4 ± 33.9, 41.4 ±
28.3, and 61.2 ± 29.8 ml/minute/1.73 m2 in these three
groups, respectively (p = 0.003). There were significant
differences in eGFR decline from baseline and de novo
CKD among groups, with PN followed by RN group
showing the worst functional outcomes (all p < 0.05).
PN followed by PN group had significantly higher latest
eGFR (p = 0.003), less eGFR decline from baseline during
the entire postoperative follow-up period (all p < 0.05).
They had also significantly less de novo CKD stage ≥3
occurred within a year after 2nd operation (p = 0.036),
less de novo CKD stage ≥3 occurred after the one-year
minimal follow-up period after 2nd operation (median/
mean follow-up period: 54.0/65.6 months, p < 0.001),
and less total number of patients with CKD at the last
follow-up than other groups. RN followed by PN group
had significantly less eGFR decline than PN followed by
RN group at postoperative 1 week (p = 0.031) and the
latest follow-up period (p = 0.001) from baseline.
We also performed another subgroup analysis between
bilateral synchronous RCC (PN followed by PN) subgroup
and unilateral RCC (single PN) subgroup (Table 3). The
bilateral synchronous RCC (PN followed by PN) subgroup
Table 1 Baseline characteristics after propensity score matching
Variables Bilateral RCC













Age, mean (SD) 54.0 ± 12.7 55.9 ± 12.9 54.2 ± 13.4 0.549
Sex, male, N (%) 74 (84.1%) 74 (82.2%) 142 (79.8%) 0.856
DM, yes, N (%) 17 (19.3%) 18 (20.0%) 22 (16.7%) 0.792
HTN, yes, N (%) 47 (53.4%) 42 (46.7%) 89 (50.0%) 0.564
BMI, mean (SD) 25.0 ± 3.7 24.2 ± 3.1 24.7 ± 3.0 0.367
ECOG performance status, N (%) 0.415
≤ 1 86 (97.7%) 86 (95.6%) 167 (93.8%)
≥ 2 2 (2.3%) 4 (4.4%) 11 (6.2)
Surgical type, N (%)











EBL, ml, mean (SD) 249.1 ± 107.5 259.0 ± 217.9 226.1 ± 261.5 0.878
Ischemic time, min, mean (SD)a 21.5 ± 9.8 22.2 ± 10.7 21.4 ± 16.3 0.904
Pathologic tumor size, mm, mean (SD) 33.5 ± 34.8 32.1 ± 27.6 32.8 ± 23.3 0.949
Baseline eGFR, ml/min/1.73 m2, mean (SD) 71.6 ± 32.5 76.0 ± 25.4 78.6 ± 22.3 0.224
Baseline CKD, stage ≥3 28 (31.8%) 16 (17.8%) 39 (21.9%) 0.068
§ Evaluates differences among all 3 groups
a Partial nephrectomy only
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had no significant difference in eGFR decline at the latest
follow-up period from baseline compared to the unilateral
RCC (single PN) subgroup (p = 0.770), although it had
higher de novo CKD rate until postoperative 1 year and
during the entire follow-up period (13.8% vs. 6.9%, p =
0.016). Additional subgroup analysis between bilateral
synchronous and metachronous RCC (PN followed by
PN) subgroups revealed no significant differences in vari-
ables among groups (Table 4).
Multivariate analysis for the prediction of de novo
CKD until postoperative 1 year revealed that hyperten-
sion (Hazard ratio [HR]: 2.159, 95% Confidence Interval
[CI]: 1.233–3.783, p = 0.007), pathologic tumor size at
1st surgery (HR: 1.012, 95% CI: 1.006–1.024, p = 0.010)
Table 2 Functional outcome of bilateral RCC cohort regardless of time interval between tumors





Preoperative eGFR, ml/min/1.73m2, mean (SD) (before 1st surgery) 84.7 ± 25.4 83.1 ± 19.6 79.6 ± 33.4 0.759
Latest eGFR, ml/min/1.73 m2, mean (SD) 79.4 ± 33.9 41.4 ± 28.3 61.2 ± 29.8 0.003
p = 0.108 a
eGFR decline from baseline, mean (SD)
Postoperative 1 week (after 2nd surgery) 6.9 ± 18.5 28.5 ± 18.2 10.6 ± 16.5 0.009
p = 0.031 a
Postoperative 1 month (after 2nd surgery) 5.1 ± 15.0 28.7 ± 23.2 9.9 ± 13.2 0.001
p = 0.058 a
Postoperative 1 year (after 2nd surgery) 5.8 ± 17.5 29.4 ± 24.2 31.3 ± 6.3 0.018
p = 0.035 a
Latest −0.64 ± 22.5 30.5 ± 26.6 −2.7 ± 21.3 0.001
p = 0.001 a
De novo CKD, stage≥3
Baseline CKD, before 1st surgery 8 (16.7%) 1 (12.5%) 5 (20.0%) 0.874
Baseline CKD, before 2nd surgery 6 (12.5%) 1 (12.5%) 9 (36.0%) 0.049
De novo, ≤ 1 year after 2nd surgery 9 (18.8%) 4 (50%) 5 (20%) 0.036
De novo, > 1 year after 2nd surgery 0 (0%) 2 (25.0%) 1 (4.0%) < 0.001
Total number of CKD patients last follow-up 15 (31.3%) 7 (87.5%) 15 (60%) < 0.001
SD Standard Deviation
eGFR follow-up duration (mean ± SD): 65.6 ± 47.6 months (range, 0–166 months)
8 patients with RN followed by RN were excluded from the analysis
§ Evaluates differences among all surgery groups at specific points
a Evaluates differences between ‘PN→ RN’ group and ‘RN→ PN’ group
Table 3 Comparative analysis between bilateral synchronous tumor subgroup (PN followed by PN) and unilateral RCC (single PN)
Variables Bilateral
(N = 58 lesions of
29 patients)
Unilateral
(N = 144 lesions of 144 patients)
P value
Preoperative eGFR, ml/min/1.73m2, mean (SD) 78.2 ± 24.3 82.2 ± 22.9 0.106
aLatest eGFR, ml/min/1.73 m2, mean (SD) 80.2 ± 22.7 83.1 ± 20.4 0.182
eGFR decline from baseline, mean (SD)
Postoperative 1 week 7.2 ± 16.1 −3.5 ± 15.4 < 0.001
Postoperative 1 month 3.5 ± 14.6 −1.7 ± 15.5 0.037
Postoperative 1 year 5.3 ± 17.3 0.9 ± 16.3 0.099
bLatest −2.0 ± 23.8 −1.0 ± 18.5 0.770
De novo CKD, ≤ 1 year 8 (13.8%) 8 (7.5%) 0.022
De novo CKD, total 8 (13.8%) 10 (6.9%) 0.016
aLatest eGFR: The very last estimated Glomerular Filtration Rate measured during the follow-up period
bLatest: The last time a patient was followed-up and evaluated eGFR
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Table 4 Comparative analysis between PN followed by PN subgroups (synchronous vs. metachronous) [latter surgery]
Variables Synchronous
(N = 29 patients)
Metachronous
(N = 19 patients)
P value
Preoperative eGFR, ml/min/1.73m2, mean (SD) 76.5 ± 22.4 82.1 ± 25.1 0.434
aLatest eGFR, ml/min/1.73 m2, mean (SD) 80.2 ± 24.0 78.1 ± 31.2 0.247
eGFR decline from baseline, mean (SD)
Postoperative 1 week 6.5 ± 18.0 7.4 ± 19.7 0.871
Postoperative 1 month 3.0 ± 14.9 8.4 ± 15.1 0.230
Postoperative 1 year 3.5 ± 17.5 9.3 ± 17.5 0.266
bLatest −3.7 ± 24.1 4.0 ± 19.5 0.250
De novo CKD, stage ≥3
Baseline CKD, Before 1st surgery 7 (24.1%) 1 (5.3%) 0.123
Baseline CKD, Before 2nd surgery 5 (17.2%) 1 (5.3%) 0.381
De novo, ≤ 1 year after 2nd surgery 5 (17.2%) 4 (21.1%) 1.000
De novo, > 1 year after 2nd surgery 0 (0%) 0 (0%) 1.000
Total number of pts. with CKD at last follow-up 10 (34.5%) 5 (26.3%) 0.751
aLatest eGFR: The very last estimated Glomerular Filtration Rate measured during the follow-up period
bLatest: The last time a patient was followed-up and evaluated eGFR
Table 5 Multivariate Cox regression analyses of variables associated with de novo CKD within postoperative one year
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (years) 1.032 1.009–1.056 0.001 1.036 1.011–1.062 0.005
BMI 1.011 0.924–1.106 0.810
Sex, male 0.711 0.348–1.454 0.350
DM 1.295 0.646–2.595 0.466
HTN 2.413 1.353–4.304 0.003 2.159 1.233–3.783 0.007
Baseline eGFR 0.992 0.982–1.003 0.150
Baseline Hb 0.986 0.875–1.112 0.822
EBL (1st surgery) 1.000 0.999–1.001 0.799
EBL (2nd surgery) 1.000 0.999–1.001 0.663
Ischemic time (1st surgery) 1.005 0.974–1.037 0.763
Ischemic time (2nd surgery) 0.987 0.957–1.019 0.431
Pathologic tumor size (1st surgery) 1.015 1.006–1.024 0.001 1.012 1.003–1.021 0.010
Pathologic tumor size (2nd surgery) 1.004 0.996–1.011 0.326
Time between operations 1.000 1.000–1.001 0.083
Surgery sequence
PN ➔ PN Reference Reference
PN ➔ RN 2.249 1.088–4.786 0.006 1.837 1.028–3.635 0.007
RN ➔ PN 1.510 1.096–5.750 0.030 1.235 0.947–5.276 0.066
PN (unilateral case) 0.663 0.285–1.543 0.341 0.315 0.119–0.832 0.261
Tumor chronology
Synchronous Reference
Metachronous 1.370 0.660–2.840 0.398
Tumor multiplicity
Unilateral Reference
Bilateral 1.244 0.698–2.215 0.459
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and PN followed by RN sequence (HR: 1.837, 95% CI:
1.028–3.635, p = 0.007) were significant factors (Table 5).
A multivariate analysis for the prediction of de novo
CKD during the entire period revealed that hypertension
(HR: 1.905, 95% CI: 1.172–3.265, p = 0.010), PN followed
by RN sequence (HR: 1.888, 95% CI: 1.088–4.055,
p < 0.001), and metachronous RCC (HR: 2.682, 95% CI:
1.032–6.973, p = 0.043) were significant predictive fac-
tors (Table 6). The difference in time interval between
tumor occurrences in metachronous RCC was not sig-
nificantly related to de novo CKD incidence (p = 0.083
for de novo CKD within postoperative 1 year and p =
0.056 for de novo CKD during the entire follow-up
period).
Discussion
Surgical management of RCC ultimately aims to balance
numerous considerations with attempts to minimize op-
erative morbidity and decline of renal function. To this
end, when technically feasible, NSS has been advocated
to maximize preservation of renal parenchyma and avoid
the incidence and sequelae of renal function deterior-
ation [19–22]. In the setting of bilateral renal masses,
guidelines favor the performance of bilateral PN when it
is technically feasible [10–12]. However, there is only a
short reference to this simple guideline statement with-
out specific details on how to do it in real clinical prac-
tice. For example, in case of the situation that both RN
and PN are inevitably needed, it is a dilemma to decide
which procedure has to be done first to achieve satisfac-
tory renal function preservation. Nevertheless, using our
prospectively collected database, we proved that doing
RN first followed by PN sequence would be better in
terms of preserving renal function than proceeding in
reverse order. According to our multivariate analysis,
hypertension and PN followed by RN sequence are com-
monly independent risk factors for de novo CKD within
postoperative 1 year and the entire follow-up period. We
also identified evidence in other literature supporting
our findings. Krohn et al. have reported that 1 year after
Table 6 Multivariate Cox regression analyses of variables associated with de novo CKD during the entire follow-up period
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (years) 1.031 1.009–1.053 0.005 1.005 0.971–1.040 0.780
BMI 1.029 0.946–1.120 0.500
Sex, male 0.607 0.306–1.205 0.154
DM 1.530 0.806–2.905 0.194
HTN 1.956 1.147–3.335 0.014 1.905 1.172–3.265 0.010
Baseline eGFR 0.992 0.982–1.002 0.106
Baseline Hb 1.002 0.902–1.114 0.969
EBL (1st surgery) 1.000 0.999–1.000 0.784
EBL (2nd surgery) 1.000 0.999–1.001 0.680
Ischemic time (1st surgery) 1.001 0.972–1.032 0.921
Ischemic time (2nd surgery) 0.985 0.956–1.014 0.301
Pathologic tumor size (1st surgery) 1.016 1.007–1.025 0.001 1.013 1.000–1.027 0.051
Pathologic tumor size (2nd surgery) 1.004 0.997–1.011 0.278
Time between operations 1.000 1.000–1.001 0.056
Surgery sequence
PN ➔ PN Reference Reference
PN ➔ RN 2.919 1.386–6.146 0.001 1.888 1.088–4.055 < 0.001
RN ➔ PN 2.190 1.165–4.114 0.015 1.041 1.003–3.258 0.103
PN (unilateral case) 0.782 0.366–1.669 0.525 0.233 0.088–0.614 0.718
Tumor chronology
Synchronous Reference Reference
Metachronous 2.250 1.121–4.516 0.023 2.682 1.032–6.973 0.043
Tumor multiplicity
Unilateral Reference
Bilateral 1.421 0.824–2.449 0.206
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donation, the remained kidney manages to compensate
up to 70% of renal function before surgery [23]. A plaus-
ible explanation is that in the remained kidney, vasodila-
tion and increased renal plasma flow can occur
immediately after surgery. These changes, combined
with the process of glomerular hypertrophy, can increase
glomerular filtration of the remnant kidney by approxi-
mately 40% without occurring a concomitant increase in
glomerular capillary pressure [24–26]. This adaptive
hyperfiltration also occurs in older kidney donors, al-
though more modestly than in younger donors [27].
Taner et al. have reported that compensatory hyper-
trophy and GFR increase can occur in the remaining
kidney of medically complex living donors at a compar-
able rate to those of standard donors [28]. These find-
ings confirmed reassurance for delicately selected
medically complex living donors. One study has con-
cluded that RCC is not an independent risk factor for
renal function decrease after nephrectomy. RCC patients
with few morbidities could have the same deterioration
of meanly 30% of kidney function compared with living
donors. However, their lower baseline function can re-
sult in an increased risk for CKD [29]. These findings
imply that patients with RN who have sufficient period
to compensate for their renal function until PN can pre-
serve favorable renal function without risk for CKD.
PN is generally related to a lower risk of developing
clinically significant CKD than RN. Postoperative im-
pairment in kidney function occurs most commonly in
the first year after nephrectomy and appears stable over
time. Age, Tumor stage, and preoperative kidney func-
tion are predictors of incident CKD after kidney cancer
operation [30]. Bilateral PN needs more careful consid-
eration compared to ipsilateral PN due to potential
additional loss of renal function secondary to bilateral
renal ischemia from hemorrhage, hypotension, and pro-
longed operative time [19]. These challenges have made
some surgeons support staged bilateral PN as opposed
to simultaneous bilateral PN in a single setting. PN, if
performed well, is also a possible choice for larger renal
tumors as it generates tolerable surgical morbidity, bet-
ter renal function preservation, and equivalent cancer
control with potential for better long-term survival than
RN [31]. Bercz et al. showed acceptable oncological and
functional outcomes from 65 patients. They reported
significant postoperative renal function deterioration
(44.8% eGFR decrease for synchronous (mostly RN→
PN) and 30.4% decrease for metachronous tumor (all
RN→ PN) after the second operation, respectively),
but hemodialysis was rarely required. Compared to
their results, we showed more eGFR preservation if
RN→ PN (23.1% decrease) is performed respectively
even though their cohort characteristics are slightly
different [32].
This study has some limitations. First, even with two
large tertiary centers’ cohort, the study population was
still small due to the rarity of bilateral RCCs with its
retrospective nature. In addition, there was no analysis
of differences in renal functions that might occur due to
the heterogeneity of surgical techniques and different
time intervals of operation for bilateral metachronous
RCC. Thirdly, our result from eight patients that PN
followed by RN can negatively affect renal function pres-
ervation is necessary to be verified in further studies
with larger numbers of patients. Finally, it was difficult
to identify genetic differences between these patients.
These issues can be elucidated if multicenter prospective
randomized clinical trials are performed in the near fu-
ture. Nevertheless, to the best of our knowledge, the
current study is the first of its kind that assesses func-
tional aspects of both kidney cancer surgery performed
in large institutions over a relatively long period of time.
This is also the first study to find that RN followed by
PN is superior in terms of preserving renal functions in
the opposite order by evaluating cohorts through pro-
pensity score matching analysis.
Conclusion
This study evaluated renal functional outcomes of bilat-
eral RCC patients after sequential kidney cancer surgery
in a large contemporary cohort. The sequence of surgery
should be prudently determined in bilateral renal tu-
mors. The best ideal scenario is PN for both tumors.
However, it is essential to make decisions about surgery
sequence in the inevitable situation of performing a
combination of radical and partial nephrectomy. PN
followed by RN showed a negative impact on renal func-
tional preservation. Thus, NSS should be considered for
all amenable bilateral RCCs.
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